Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:2013:963520.
doi: 10.1155/2013/963520. Epub 2013 Dec 5.

ROS and brain diseases: the good, the bad, and the ugly

Affiliations
Review

ROS and brain diseases: the good, the bad, and the ugly

Aurel Popa-Wagner et al. Oxid Med Cell Longev. 2013.

Abstract

The brain is a major metabolizer of oxygen and yet has relatively feeble protective antioxidant mechanisms. This paper reviews the Janus-faced properties of reactive oxygen species. It will describe the positive aspects of moderately induced ROS but it will also outline recent research findings concerning the impact of oxidative and nitrooxidative stress on neuronal structure and function in neuropsychiatric diseases, including major depression. A common denominator of all neuropsychiatric diseases including schizophrenia and ADHD is an increased inflammatory response of the brain caused either by an exposure to proinflammatory agents during development or an accumulation of degenerated neurons, oxidized proteins, glycated products, or lipid peroxidation in the adult brain. Therefore, modulation of the prooxidant-antioxidant balance provides a therapeutic option which can be used to improve neuroprotection in response to oxidative stress. We also discuss the neuroprotective role of the nuclear factor erythroid 2-related factor (Nrf2) in the aged brain in response to oxidative stressors and nanoparticle-mediated delivery of ROS-scavenging drugs. The antioxidant therapy is a novel therapeutic strategy. However, the available drugs have pleiotropic actions and are not fully characterized in the clinic. Additional clinical trials are needed to assess the risks and benefits of antioxidant therapies for neuropsychiatric disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of oxidative stress-related mechanisms underlying disease development in Alzheimer's disease (AD), Parkinson disease (PD), stroke, attention deficit and hyperactivity disorders (ADHD), schizophrenia, and depression.

References

    1. Dole M. The natural history of oxygen. The Journal of General Physiology. 1965;49(1):5–27. - PMC - PubMed
    1. Campbell NA, Reece JB. Biology. 7th edition. Pearson-Benjamin Cummings; 2005.
    1. Rich PR. The molecular machinery of Keilin’s respiratory chain. Biochemical Society Transactions. 2003;31(6):1095–1105. - PubMed
    1. Guglielmotto M, Tamagno E, Danni O. Oxidative stress and hypoxia contribute to Alzheimer’s disease pathogenesis: two sides of the same coin. TheScientificWorldJournal. 2009;9(1):781–791. - PMC - PubMed
    1. Chen S-D, Yang D-I, Lin T-K, Shaw F-Z, Liou C-W, Chuang Y-C. Roles of oxidative stress, apoptosis, PGC-1 and mitochondrial biogenesis in cerebral ischemia. International Journal of Molecular Sciences. 2011;12(10):7199–7215. - PMC - PubMed

Publication types